| Market Capitalization (Millions $) |
448 |
| Shares
Outstanding (Millions) |
44 |
| Employees |
344 |
| Revenues (TTM) (Millions $) |
99 |
| Net Income (TTM) (Millions $) |
-261 |
| Cash Flow (TTM) (Millions $) |
-65 |
| Capital Exp. (TTM) (Millions $) |
14 |
Regenxbio Inc
Regenxbio Inc is a leading biotechnology company, headquartered in Maryland, USA.
The company specializes in developing gene therapies for the treatment of genetic diseases.
Established in 2008, Regenxbio has quickly gained recognition for its innovative approach in the field of gene therapy.
The company uses proprietary viral vectors to deliver genes to specific cells in the body, aiming to correct the genetic defects that cause various diseases.
Regenxbioes gene therapy approach holds promise for the treatment of a range of genetic disorders, including rare diseases.
Regenxbio currently has several gene therapy candidates under development, targeting different disorders, including Angelman syndrome, Huntingtones disease, and retinal disorders.
The companyes lead candidate, RGX-314, is being developed for the treatment of wet age-related macular degeneration (AMD).
RGX-314 has already shown impressive results in clinical trials, demonstrating its potential as a game-changer for the treatment of AMD.
In addition to its gene therapy pipeline, Regenxbio has collaborations with several leading biotech and pharmaceutical companies.
These collaborations are aimed at leveraging Regenxbioes technology to develop new gene therapies for various indications, including neurodegenerative diseases and cancer.
Regenxbio has a team of experienced professionals, including scientists, researchers, and medical experts.
The companyes leadership team is composed of industry experts, and its board of directors includes renowned physicians, scientists, and business leaders.
Regenxbio has received significant funding from several venture capital firms and investors.
Overall, Regenxbio Inc is a promising biotechnology company that is at the forefront of developing gene therapies for the treatment of various genetic diseases.
With its strong pipeline of gene therapy candidates and collaborations with leading partners, the company is well-positioned for long-term growth and success.
Company Address: 9804 Medical Center Drive Rockville 20850 MD
Company Phone Number: 552-8181 Stock Exchange / Ticker: NASDAQ RGNX
|
